Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPTNASDAQ:ERASNASDAQ:FULCNASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.26+0.7%$4.09$1.80▼$4.50$370.71M1.181.38 million shs8.63 million shsERASErasca$1.45+31.8%$1.29$1.01▼$3.45$410.77M1.121.72 million shs3.99 million shsFULCFulcrum Therapeutics$7.07+2.5%$4.32$2.32▼$10.13$372.46M2.29971,501 shs752,851 shsIMUXImmunic$0.68-25.3%$1.01$0.56▼$2.11$87.21M1.73757,753 shs9.23 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics+0.71%+2.16%+3.90%+48.95%+132.79%ERASErasca+31.82%+19.83%+1.40%+5.84%-39.83%FULCFulcrum Therapeutics+2.46%+15.52%+93.70%+96.94%-9.01%IMUXImmunic-25.28%-26.13%-46.87%-42.85%-44.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKPTCheckpoint Therapeutics2.431 of 5 stars1.24.00.04.22.70.80.0ERASErasca3.5991 of 5 stars4.51.00.00.03.52.51.3FULCFulcrum Therapeutics0.5624 of 5 stars1.31.00.00.02.72.50.0IMUXImmunic2.8543 of 5 stars3.64.00.00.03.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.331.72% UpsideERASErasca 3.00Buy$4.57215.27% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$6.29-11.09% DownsideIMUXImmunic 3.25Buy$11.601,605.63% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, CKPT, FULC, and ERAS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.005/29/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $10.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/23/2025IMUXImmunicB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $5.005/16/2025IMUXImmunicWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform5/15/2025FULCFulcrum TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$10.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/1/2025IMUXImmunicHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/30/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K9,041.59N/AN/A($0.47) per share-9.06ERASErascaN/AN/AN/AN/A$2.10 per shareN/AFULCFulcrum Therapeutics$80M4.77N/AN/A$3.80 per share1.86IMUXImmunicN/AN/AN/AN/A$0.64 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%8/11/2025 (Estimated)ERASErasca-$125.04M-$0.62N/AN/AN/AN/A-42.26%-34.97%8/11/2025 (Estimated)FULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)IMUXImmunic-$93.61M-$1.23N/AN/AN/AN/A-169.55%-118.96%8/14/2025 (Estimated)Latest IMUX, CKPT, FULC, and ERAS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025IMUXImmunic-$0.25-$0.25N/A-$0.25N/AN/A5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/20/2025Q4 2024ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AERASErascaN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29ERASErascaN/A11.0011.00FULCFulcrum TherapeuticsN/A18.4418.44IMUXImmunicN/A2.712.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%ERASErasca67.78%FULCFulcrum Therapeutics89.83%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%ERASErasca14.40%FULCFulcrum Therapeutics7.00%IMUXImmunic3.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableERASErasca120283.29 million221.94 millionOptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionableIMUXImmunic7095.82 million87.38 millionOptionableIMUX, CKPT, FULC, and ERAS HeadlinesRecent News About These CompaniesImmunic announces public offering of warrants to fund trialsMay 30 at 4:54 AM | investing.comImmunic shares fall 12% after pricing of $65 million underwritten public offering to fund trialsMay 29 at 6:52 PM | msn.comImmunic unveils pricing of $65M underwritten public offeringMay 29 at 8:22 AM | proactiveinvestors.comImmunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public OfferingMay 29 at 7:05 AM | prnewswire.comImmunic, Inc. Announces Proposed Public OfferingMay 28 at 4:02 PM | prnewswire.comImmunic (NASDAQ:IMUX) Receives Buy Rating from B. RileyMay 25, 2025 | marketbeat.comImmunic Analyst Ratings and Price Targets | NASDAQ:IMUX | BenzingaMay 24, 2025 | benzinga.comJanus Henderson Group PLC Cuts Stock Holdings in Immunic, Inc. (NASDAQ:IMUX)May 23, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Given Consensus Rating of "Buy" by AnalystsMay 22, 2025 | americanbankingnews.comImmunic, Inc. (NASDAQ:IMUX) Given Average Rating of "Buy" by AnalystsMay 19, 2025 | marketbeat.comImmunic (IMUX) Expected to Announce Quarterly Earnings on WednesdayMay 9, 2025 | marketbeat.comWilliam Blair Analysts Boost Earnings Estimates for ImmunicMay 6, 2025 | marketbeat.comLeerink Partnrs Has Bullish Estimate for Immunic Q2 EarningsMay 6, 2025 | marketbeat.comResearch Analysts Issue Forecasts for Immunic Q1 EarningsMay 4, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Receives "Buy" Rating from HC WainwrightMay 3, 2025 | marketbeat.comImmunic Reports Positive Data From Phase 2 CALLIPER Study Of Vidofludimus CalciumMay 2, 2025 | nasdaq.comD. Boral Capital Reiterates "Buy" Rating for Immunic (NASDAQ:IMUX)May 2, 2025 | marketbeat.comImmunic to Participate in Scientific and Industry Conferences in MayMay 2, 2025 | prnewswire.comImmunic, Inc. (NASDAQ:IMUX) Shares Sold by Adage Capital Partners GP L.L.C.May 2, 2025 | marketbeat.comImmunic Talks Up Disability Gains as Phase II MS Therapy Fails on Primary EndpointMay 1, 2025 | biospace.comMS drug shows promise in progressive cases, despite missed trial goalMay 1, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, CKPT, FULC, and ERAS Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPT$4.26 +0.03 (+0.71%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$4.29 +0.03 (+0.61%) As of 05/29/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Erasca NASDAQ:ERAS$1.45 +0.35 (+31.82%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$1.44 -0.01 (-0.62%) As of 04:44 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Fulcrum Therapeutics NASDAQ:FULC$7.07 +0.17 (+2.46%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$7.06 0.00 (-0.07%) As of 05/29/2025 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Immunic NASDAQ:IMUX$0.68 -0.23 (-25.28%) Closing price 05/29/2025 04:00 PM EasternExtended Trading$0.73 +0.05 (+7.34%) As of 04:55 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
